We are live on ! Find out more
TAM

TFG Asset Management Portfolio holdings

AUM $635M
1-Year Est. Return 28.07%
This Fund
S&P 500
This Quarter Est. Return
-16.4%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$515M
AUM Growth
+$40.8M
Cap. Flow
+$154M
Cap. Flow %
29.83%
Top 10 Hldgs %
82.02%
Holding
40
New
12
Increased
15
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
PATH icon
UiPath
PATH
+$98.8M
2
WBD icon
Warner Bros
WBD
+$25.9M
3
WK icon
Workiva
WK
+$6.97M
4
SLNO
Soleno Therapeutics
SLNO
+$4M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.46M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$4.46M
2
ANNX icon
Annexon
ANNX
+$4.17M
3
FOLD
Amicus Therapeutics
FOLD
+$3.71M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$2.17M
5
ZVRA icon
Zevra Therapeutics
ZVRA
+$1.72M

Sector Composition

Rank Sector Weight
1 Technology 62.65%
2 Healthcare 23.94%
3 Energy 7.28%
4 Communication Services 4.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PATH icon
1
UiPath
PATH
$8.64B
$280M 54.32%
25,207,628
+7,757,628
+44% +$98.8M
KGEI
2
Kolibri Global Energy
KGEI
$200M
$37.5M 7.28%
6,834,504
-100,000
-1% -$422K
WBD icon
3
Warner Bros
WBD
$69.6B
$25.4M 4.92%
+923,725
New +$25.9M
WK icon
4
Workiva
WK
$3.7B
$14.9M 2.89%
250,000
+100,000
+67% +$6.97M
LYFT icon
5
Lyft
LYFT
$6.48B
$13.3M 2.58%
1,000,000
– –
CXM icon
6
Sprinklr
CXM
$1.65B
$13.2M 2.56%
2,200,000
– –
AUTL
7
Autolus Therapeutics
AUTL
$591M
$13.1M 2.55%
9,500,000
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$3.52B
$9.91M 1.92%
312,316
+68,516
+28% +$1.87M
ARWR icon
9
Arrowhead Research
ARWR
$12.1B
$7.98M 1.55%
127,198
+30,263
+31% +$1.92M
NKTR icon
10
Nektar Therapeutics
NKTR
$2.57B
$7.41M 1.44%
103,037
+33,750
+49% +$1.92M
ANNX icon
11
Annexon
ANNX
$862M
$7.16M 1.39%
1,292,455
-740,000
-36% -$4.17M
PHVS icon
12
Pharvaris
PHVS
$2.55B
$6.26M 1.22%
221,611
+26,999
+14% +$721K
AXSM icon
13
CALL
Axsome Therapeutics
AXSM
$11.2B
$5.92M 1.15%
+35,000
New +$6.05M
ALKS icon
14
Alkermes
ALKS
$8.44B
$5.65M 1.1%
159,791
+18,619
+13% +$578K
AGIO icon
15
Agios Pharmaceuticals
AGIO
$2B
$5.58M 1.08%
164,839
+2,821
+2% +$80K
IMVT icon
16
Immunovant
IMVT
$8.64B
$5.43M 1.05%
218,507
+52,320
+31% +$1.35M
PRAX icon
17
Praxis Precision Medicines
PRAX
$10.3B
$5.14M 1%
15,952
-7,000
-30% -$2.17M
KRYS icon
18
Krystal Biotech
KRYS
$9.72B
$5.08M 0.99%
19,668
+7,854
+66% +$2.09M
DYN icon
19
Dyne Therapeutics
DYN
$4.85B
$4.68M 0.91%
258,132
+10,135
+4% +$175K
AMLX icon
20
Amylyx Pharmaceuticals
AMLX
$2.6B
$4.42M 0.86%
317,877
+45,049
+17% +$634K
MBX
21
MBX Biosciences
MBX
$3.23B
$4.34M 0.84%
145,480
+2,153
+2% +$73.2K
DFTX
22
Definium Therapeutics
DFTX
$5.9B
$3.78M 0.73%
+199,994
New +$3.39M
SLNO
23
DELISTED
Soleno Therapeutics
SLNO
$3.42M 0.66%
+102,125
New +$4M
AXSM icon
24
Axsome Therapeutics
AXSM
$11.2B
$3.39M 0.66%
20,059
-6,875
-26% -$1.19M
HRMY icon
25
Harmony Biosciences
HRMY
$2.24B
$3.34M 0.65%
119,340
+36,516
+44% +$1.2M
1
2

Similar funds

AP
Affinity Partners Sunny Isles Beach, Florida $635M AUM 43.43% 1-Year Est. Return
WCM
Woodson Capital Management Greenwich, Connecticut $636M AUM 39.33% 1-Year Est. Return
FTC
Farmers Trust Company Youngstown, Ohio $637M AUM 23.14% 1-Year Est. Return
KCM
Kultura Capital Management Park City, Utah $638M AUM
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return

TFG Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, TFG Asset Management held 40 positions worth $515M, up 8.6% from $474M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

TFG Asset Management deployed $154M of net new capital in Q1 2026, opening 12 new positions and adding to 15 existing holdings. Its largest new stake was Warner Bros: 923,725 shares worth $25.4M.

By sector, the portfolio is most concentrated in Technology at 63% of assets, down from 71% a quarter earlier, followed by Healthcare and Energy.

On the sell side, the largest reduction was Annexon, an estimated $4.17M trimmed.

  • TFG Asset Management's largest Q1 2026 buy was Warner Bros: 923,725 shares worth $25.4M.
  • TFG Asset Management added most to UiPath in Q1 2026, an estimated $98.8M increase.
  • TFG Asset Management's biggest Q1 2026 reduction was Annexon, cutting an estimated $4.17M.
  • TFG Asset Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $4.46M.
  • TFG Asset Management's ten largest holdings make up 82% of its $515M portfolio in Q1 2026.
  • TFG Asset Management opened 12 new positions and closed 4 in Q1 2026.
  • TFG Asset Management's portfolio value rose 8.6% quarter-over-quarter to $515M.

Based on TFG Asset Management's 13F filing for Q1 2026, filed 15 May 2026.